Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction

Qianfoshan Hospital300 enrolled

Overview

To develop and externally validate a machine learning model for predicting the 1-year risk of relapse in patients with stable ABPA, and to further evaluate its value in risk stratification and clinical decision-making.

This project aims to develop an inflammatory phenotype-based risk prediction model for recurrence of allergic bronchopulmonary aspergillosis (ABPA) to enable stratified patient management. The study integrates multidimensional data sources, including radiomics, mycobiomics, inflammatory biomarkers, pulmonary function parameters, and routine clinical records. Deep machine learning algorithms are employed to extract and select key features from these multi-omics and clinical datasets, define inflammatory phenotypes, and subsequently construct a recurrence risk prediction model. Based on the risk stratification derived from the model, low-risk individuals will receive regular follow-up, whereas high-risk individuals will undergo intensified intervention and management. This approach is expected to optimize individualized treatment strategies for ABPA patients, reduce recurrence rates, and improve clinical outcomes.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Allergic Bronchopulmonary Aspergillosis (ABPA)Machine Learning Multi-omics Multicenter Study Relapse

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female and Male patients aged 18-80 years * diagnosis of Allergic Bronchopulmonary Aspergillosis ABPA accroding to the 2024 ISHAM Working Group Diagnostic Criteria Exclusion Criteria: * Patients with malignant tumors or severe organ dysfunction (e.g., cardiac, cerebral, renal, etc.) * Patients with severe comorbidities, including active pulmonary tuberculosis, lung cancer, chronic heart failure (NYHA class Ⅳ), chronic kidney disease (CKD stage 5), decompensated cirrhosis, etc. * Patients with immunosuppressive status, such as HIV infection, long-term use of oral corticosteroids or immunosuppressive agents. * Pregnant or lactating women. * Patients with missing key data or incomplete medical records.

Locations (1)

Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China, Jinan, Shandong 250014

Jinan, Shandong, China

RECRUITING

Outcomes

Primary Outcomes

Recurrent disease occurs in patients during the remission period.

Observe whether disease recurrence occurs in ABPA patients who have reached stable phase after treatment. Stable Phase： 1. Symptomatic improvement by at least 50% (on a Likert or visual analog scale) after eight weeks; and, 2. Major radiological improvement (\>50% reduction in radiologic opacities) or decline in serum total IgE by at least 20% after eight weeks of treatment. Exacerbation/Recurrence: In a patient with diagnosed ABPA 1. Sustained (\>14 days) clinical worsening, or 2. Radiological worsening, and 3. Increase in serum total IgE by ≥50% from the last recorded IgE value during clinical stability, along with 4. Exclusion of other causes of worsening.

Time frame: 1 year

Central Contacts

Qian Qi

CONTACT

+86 13706380314 qiqianqlh@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.